749849-14-7

Basic information

• Product Name: 6-BROMOIMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID
• Synonyms: 6-BROMOIMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID;BUTTPARK 154\50-31;6-BROMOIMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID, 95+%;IMidazo[1,2-a]pyridine-2-carboxylic acid, 6-broMo-;6-BroMoiMidazo[1,2-a]pyridine-2-carboxylic acid hydrate, 95%;6-Bromoimidazo[1,2-a]pyridine-2-carboxylicacid 97%
• CAS NO: 749849-14-7
• Molecular Formula: C₈H₅BrN₂O₂
• Molecular Weight: 241.04
• EINECS: 201-215-5
• Product Categories: Carboxylic Acids;Carboxylic Acids;Fused Ring Systems;Heterocycle-Pyridine series
• Mol File: 749849-14-7.mol

Chemical Properties

• Appearance: /
• Density: 1.89
• Refractive Index: 1.728
• Storage Temp.: 2-8°C
• PKA: -4.73±0.41(Predicted)
• CAS DataBase Reference: 6-BROMOIMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMOIMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID(749849-14-7)
• EPA Substance Registry System: 6-BROMOIMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID(749849-14-7)

Safety Data

• Hazardous Substances Data: 749849-14-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
6-BROMOIMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID is used as a key intermediate in the synthesis of new drugs targeting specific biological pathways. Its unique structure allows for the development of compounds with potential therapeutic effects against various diseases.
Used in Antimicrobial and Antifungal Applications:
6-BROMOIMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID is used as an antimicrobial and antifungal agent due to its ability to inhibit the growth of certain microorganisms. This property makes it a valuable component in the development of new antibiotics and antifungal medications.
Used in Corrosion Inhibition:
6-BROMOIMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID is used as a corrosion inhibitor in various industrial applications. Its chemical properties enable it to protect metal surfaces from corrosion, extending the lifespan of equipment and infrastructure.
Used in Organic Synthesis as a Reagent:
6-BROMOIMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID is used as a reagent in organic synthesis, facilitating the formation of new compounds through chemical reactions. Its presence in these reactions can lead to the creation of novel organic molecules with potential applications in various fields.

InChI:InChI=1/C8H5BrN2O2/c9-5-1-2-7-10-6(8(12)13)4-11(7)3-5/h1-4H,(H,12,13)

Upstream product

• 67625-37-0 ethyl 6-bromoimidazo<1,2-a>pyridine-2-carboxylate 
• 1072-97-5 5-bromo-2-pyridylamine 

Downstream Products

• 1296199-88-6 6-(2-aminopyrimidin-4-yl)-N-(3-methoxybenzyl)imidazo[1,2-a]pyridine-2-carboxamide 
• 1296199-87-5 N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-2-carboxamide 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS

The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.

BICYCLIC HETEROARYLS AS KINASE INHIBITORS

The invention is directed to heteroaryl compounds useful as inhibitors of various kinase enzymes. In various embodiments, the invention provides a heteroaryl compound having inhibitory bioactivity with respect to a Rho kinase, an AKT kinase, a p70S6K kinase, a LIM kinase, an IKK kinase, a Flt kinase, an Aurora kinase, or a Src kinase, or any combination thereof. Compounds of the invention include bicyclic heteroaryl compounds of formula (I), which can contain a bridging nitrogen atom at a ring junction. The invention further provides methods of synthesis of compounds of the invention, pharmaceutical compositions, pharmaceutical combinations, and methods of treatment of malconditions using compounds of the invention.

A novel series of imidazo[1,2-a]pyridine derivatives as HIF-1α prolyl hydroxylase inhibitors

Utilizing modeling information from a recently resolved structure of human HIF-1α prolyl hydroxylase (EGLN1) and structure-based design, a novel series of imidazo[1,2-a]pyridine derivatives was prepared. The activity of these compounds was determined in a